Home Biotech Mailbag: Duchenne Drama, CAR-T Trouble, ASCO
 

Keywords :   


Biotech Mailbag: Duchenne Drama, CAR-T Trouble, ASCO

2015-06-05 15:01:16| Biotech - Topix.net

It's weird, somewhat inappropriate and definitely risky for Biomarin given its DMD drug drisapersen is currently under FDA review. Sarepta Therapeutics If you're unsure what Steven is referring to, Biomarin and PTC Therapeutics are co-sponsoring an investor "symposium" on June 22 in New York City titled, Advances in Duchenne Muscular Dystrophy Natural History and Biomarkers .

Tags: cart trouble drama biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Producers to be paid grid premiums for AngusLink beef scores
18.05This Week in Agribusiness, May 18, 2024
18.05This Week in Agribusiness, May 18, 2024
18.05Unpaid carers being forced to repay 250m to DWP
18.05Weekly Recap: Hempel, Axalta, KANSAI HELIOS Top This Weeks Stories
18.05Eastern North Pacific Tropical Weather Outlook
More »